Plby Group Inc
Change company Symbol lookup
Select an option...
PLBY Plby Group Inc
SVFA SVF Investment Corp
ROIUF Route1 Inc
MPB Mid Penn Bancorp Inc
NWSA News Corp
BAC Bank of America Corp
BA Boeing Co
EGRNF China Evergrande Group
SHYF Shyft Group Inc
NGS Natural Gas Services Group Inc
Go

Consumer Discretionary : Textiles, Apparel & Luxury Goods | Small Cap Growth
Company profile

PLBY Group, Inc., formerly Mountain Crest Acquisition Corp, is a leisure lifestyle company and owner of Playboy brand. The Company is principally engaged in connecting consumers around the world with products, services, and experiences. It has three reportable segments: Licensing, which includes licensing of Playboy brands to third parties; Direct-to-Consumer, including sales of third-party products through its owned-and-operated ecommerce platforms; and Digital Subscriptions and Content, including the sale of subscriptions to Playboy programming and trademark licensing for online gaming products. The Company's products are classified under four market categories: Sexual Wellness, including intimacy products and lingerie; Style and Apparel, including a variety of apparel and accessories products for men and women; Gaming and Lifestyle, such as digital gaming, hospitality and spirits; and, Beauty and Grooming, including fragrance, skincare, grooming and cosmetics for women and men.

Closing Price
$22.94
Day's Change
0.06 (0.26%)
Bid
--
Ask
--
B/A Size
--
Day's High
23.50
Day's Low
22.71
Volume
(Heavy Day)
Volume:
1,909,836

10-day average volume:
792,802
1,909,836

FDA committee to discuss COVID-19 booster shots

3:46 pm ET September 2, 2021 (MarketWatch)
Print

An influential Food and Drug Administration advisory committee plans to meet Sept. 17 to discuss extra doses of the COVID-19 vaccines, including the application filed by BioNTech SE (BNTX) and Pfizer Inc. (PFE) for a third dose of their COVID-19 shot. Moderna Inc. (MRNA) on Wednesday also submitted its application for a booster dose of its COVID-19 vaccine. The FDA's Vaccines and Related Biological Products Advisory Committee traditionally recommends whether the FDA should authorize or approve a vaccine or drug. The regulator is not required to follow the advice of the committee but it often does. The Biden administration previously said that COVID-19 booster shots will be available to adults starting Sept. 20, though availability will be dependent on a stamp of approval from the FDA and the Centers for Disease Control and Prevention. "The FDA will review the supplemental application as expeditiously as possible, while still doing so in a thorough and science-based manner," Dr. Peter Marks, the director of the FDA's Center for Biologics Research and Evaluation, said in a statement on Wednesday.

-Jaimy Lee

	

(END) Dow Jones Newswires

September 02, 2021 15:46 ET (19:46 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.